Cytovia Therapeutics
↗Aventura, Florida, USA
Cytovia Therapeutics is an AI-powered discovery engine focused on developing advanced immune therapeutics for cancer and other challenging unmet medical needs in oncology and immunology. The company specializes in two complementary technology platforms: (1) iPSC-derived Natural Killer (NK) cells, including unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNK cells) for tumor-specific targeting, and (2) a quadrivalent multispecific antibody platform (Flex-NK™) designed to engage natural killer cells by targeting NKp46. These platforms are being developed to treat both solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma, as well as hematological malignancies such as refractory multiple myeloma. The company combines precision gene editing with stem cell engineering to create off-the-shelf, universally applicable NK cell therapies with enhanced efficacy and persistence.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immuno-Oncology - NK Cell Therapy
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$11.56M
Investors:Immune Pharmaceuticals, Loyal VC, TF Capital, YF Capital, BioTrack Capital, Ruihua Capital, TG Sino-Dragon Fund (backed by TigerMed)
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Cell therapy (iPSC-derived NK cells), Gene therapy (TALEN® gene-edited cells), CAR-NK cells, Bispecific antibodies (Flex-NK™)
Active Trials:2
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CytoLynx Therapeutics (joint venture focused on Greater China development and commercialization)
Key Partnerships:Cellectis (TALEN® gene-editing technology collaboration, $760M+ milestone deal), New York Stem Cell Foundation (NYSCF) - iPSC-derived NK cell development, CytoImmune Therapeutics (acquired EGFR CAR-NK technology), Hebrew University of Jerusalem (scientific partnership), INSERM (scientific partnership), University of California San Francisco (UCSF) (scientific partnership), NAYA Biosciences (acquired CYT-303 and CYT-338 global rights)
COMPETITION
Position:Emerging
Competitors:Affimed, Artiva Biotherapeutics, Catamaran Bio, Dragonfly Therapeutics, Fate Therapeutics, Kiadis Pharma, Nkarta Therapeutics, ONK Therapeutics +2 more
LEADERSHIP
Key Executives:
Daniel Teper - Co-Founder, Chairman, and Chief Executive Officer
Gilles Seydoux - Co-Founder
Luca Scavo - Chief Financial Officer
James Priour - Chief Product Officer
Stanley Frankel - Chief Medical Officer
Wei Li - Chief Scientific Officer
Elysa Mantel - Vice President, General Counsel and Corporate Secretary
Tony Arulanandam, DVM, PhD - Executive Leadership
Scientific Founders:Dr. Jean Kadouche - Global Head of Antibody R&D
Board Members:Jason Aryeh - Long-time biotech investor and board director
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cytovia Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.